Study finds no evidence of IOLA in winter 2023 CIRD samples

A targeted PCR study published June 26, 2026, delivers a clear answer to one of the more closely watched questions from the winter 2023 atypical canine infectious respiratory disease outbreak: in this dataset, IOLA was not found. Investigators tested 777 veterinarian-submitted canine respiratory samples and found no confirmed IOLA-positive cases after applying a dual-target PCR strategy aimed at both the organism’s 16S rRNA gene and PrfA. (frontiersin.org)

That matters because IOLA, short for “Infectious Organism Lurking in Human Airways,” had become part of the outbreak conversation after preliminary metagenomic work suggested partial sequence similarity in canine samples. IOLA was first described in humans and remains poorly characterized, uncultured, and taxonomically difficult to place. During the 2023 outbreak, some academic and diagnostic groups publicly noted the possibility that an IOLA-like organism could be involved, while also stressing that causation had not been established. (frontiersin.org)

In the new study, the authors first used bacterial 16S targeted sequencing to triage samples. Of the 777 swabs received by the Kansas State Veterinary Diagnostic Laboratory between November 2023 and March 2024, 55 contained reads assigned to the order Rickettsiales, the lowest taxonomic level the team considered reliable for IOLA-related screening. Those 55 samples then underwent PCR testing for two IOLA-associated targets. Forty-five were negative on the 16S assay, 10 produced bands near the expected 16S size, and all were negative on the PrfA assay. Sanger sequencing of representative 16S amplicons showed non-specific amplification rather than true IOLA sequence, leading the authors to classify all 55 as negative. (frontiersin.org)

The methodological point may be as important as the negative result itself. The study found that even primers designed to match the IOLA reference sequence could still amplify non-target bacterial DNA in respiratory specimens. The authors argue that this is exactly why multi-target confirmation matters when labs investigate a putative novel pathogen. Their assay’s analytical sensitivity was about 10^4 copies/µL for both targets, and they note that low-abundance organisms could still be missed, so the paper does not prove IOLA can never be present in dogs. It does, however, argue against IOLA as a prevalent, molecularly detectable driver of the outbreak samples they studied. (frontiersin.org)

That conclusion fits with the more cautious expert tone that emerged as the 2023 respiratory disease story evolved. Cornell’s Animal Health Diagnostic Center advised clinicians at the time to test early in the disease course and before treatment when possible, noting that delayed sampling and prior therapy can reduce diagnostic yield. University of Missouri clinicians also warned against overinterpreting the presence of a newly detected organism, emphasizing that known pathogens, sampling site, and disease localization all affect what shows up on a swab. Later Frontiers work on winter 2023–2024 cases likewise suggested the surge was unlikely to be explained by a single novel pathogen and highlighted the frequency of negative results, prior antibiotic exposure, and the possibility that lower-airway disease or missed bacterial targets contributed to inconclusive testing. (vet.cornell.edu)

Why it matters: For veterinary professionals, this is a useful course correction. The study doesn’t solve atypical CIRD, but it does reduce the likelihood that IOLA should be a primary suspect in routine diagnostic thinking. It also underscores a broader surveillance challenge: when cases are severe, prolonged, or panel-negative, there’s understandable pressure to identify something new. But this paper shows how easily preliminary sequence signals can outrun validation. For clinicians and diagnostic labs, the practical takeaway is to keep emphasizing sample timing, sample quality, lower-airway collection when indicated, and interpretation in the context of known CIRDC agents and coinfections, rather than pivoting too quickly to an unverified organism. (frontiersin.org)

There’s also a communication angle for practices working with concerned pet parents. Public concern during late 2023 was amplified by reports of treatment-resistant coughing dogs and severe pneumonia, especially in dogs with exposure to boarding, daycare, or parks. This study gives veterinarians firmer footing to explain that one high-profile novel-pathogen hypothesis did not hold up under targeted testing, even as unanswered cases remain. That’s a more reassuring and more honest message than either dismissing pet parent concern or overstating certainty. (vet.cornell.edu)

What to watch: The next phase will likely center on more sensitive assays, broader bacterial detection strategies, and studies that pair upper-airway and lower-airway samples with better clinical follow-up, especially for dogs that remain negative on standard panels or have already received antibiotics before sampling. (frontiersin.org)